Chinese Medical Association updates lung cancer diagnosis and treatment guideline for 2026

The 2026 Chinese lung cancer guideline adds AI and opportunistic screening in low-dose CT, expands molecular testing, and updates treatment regimens for NSCLC, including perioperative, consolidation immunotherapy, and targeted therapy for EGFR, ALK, KRAS, HER2, and MET alteratio…

• Issued by the Oncology Society of Chinese Medical Association, replacing the 2025 edition.
• Screening updates: detailed quality control for LDCT, introduction of opportunistic screening, and integration of AI technologies.
• Pathology and treatment updates: new molecular testing recommendations, revised perioperative/consolidation regimens, refined EGFR-mutant strategies, and newly approved targeted therapies for ALK, KRAS G12C, HER2, and MET.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.